Extended Data Fig. 7: Trends emerge with post-infusion activation/differentiation state of IMA203 T-cells association with responses and depth of responses.

a) Memory phenotype associates with responses 2 weeks post-infusion. Changes in central memory phenotype (CCR7⁺ CD45RA^-) from post-infusion (week 2) to FP were compared between non-responders (n=19) vs. responders (n=19). b) Changes in activation/differentiation markers post-infusion at week 2 or week 2 compared to FP between non-responders (n=19) vs. responders (n=20). Week 2 %CD27 expression in tetramer-positive CD8⁺ T-cells and the difference between week 2 to FP for %CD45RO-expressing tetramer-positive CD8⁺ T-cell ratio. c) Changes in activation/exhaustion markers post-infusion (week 2) compared to FP associates with clinical responses. Changes in TIGIT and PD-1-expressing tetramer-positive CD8⁺ T-cell ratio from product level to week 2 post-infusion in non-responders (n=19) vs. responders (n=19). Group comparisons were performed using a two-tailed Mann-Whitney test with 95% confidence interval. A two-tailed Spearman r correlation with 95% confidence interval was performed for correlation analysis. The p-values and correlation coefficients are depicted in the respective graphs. The bar inside the violin plots represents the median value and each point represents one patient and the respective BOR (color-coded) according to RECIST1.1. Gating strategy is depicted in Supplementary Fig. 20. BOR: best overall response; CM: central memory T-cells; cPR: confirmed partial response; FP: final product; NR: non-responder; PD: progressive disease; PFS: progression-free survival; PR: partial response; R: responder; RECIST: Response Evaluation Criteria in Solid Tumors; SD: stable disease.